http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022200468-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59ec37318623e42970ac9b8cc9e49559 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5f81d4cd579eb009e51305c224e3282e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-16 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-16 |
| filingDate | 2022-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13b5bd847cd228ae2b578d7a79d00c12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe1380645bd061270760795c45d5f5ad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_288a9946bc633660d17a5d540b5d789f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6d986bab352ae1f226e128331d092b4 |
| publicationDate | 2022-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2022200468-A1 |
| titleOfInvention | Use of pantethine for the treatment of sars cov-2 infections |
| abstract | SARS-CoV and SARS-CoV-2 share similar pathogenic pathways that interact with pathways of cellular cholesterol metabolism. Depletion of cholesterol from cell membranes reduced the infectivity of SARS-CoV by 90%. Several studies reported that pantethine was able to reduce total cholesterol levels and total fatty acids synthesis but its anti-SARS CoV-2 activity has never been investigated. The inventors now demonstrate that pantethine is highly effective in the control of SARS-CoV-2 infections in vitro. In particular, the inventors show that the effect of pathethine on the inhibition of the replication of SARS-CoV-2 is interested at the dose of 100 μM (inhibition is around 76%) and the most effective concentration is 1000 μM (inhibition is around 98%). Pantethine treatments were able to reduce significantly the expression of the viral Spike and Nucleocapsid proteins and the accessory proteins ORF6. Thus the present invention relates to the use of pantethine for the treatment of a SARS CoV-2 infection. |
| priorityDate | 2021-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 215.